Allspring Global Investments
AGIO icon

Allspring Global Investments’s Agios Pharmaceuticals AGIO Stock Holding History

Allspring Global Investments’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-425
Closed -$18.9K – 1763
2024
Q3 		$18.9K Buy
425
+46
+12% +$2.09K ﹤0.01% 2016
2024
Q2 		$16.3K Sell
379
-272
-42% -$9.82K ﹤0.01% 2156
2024
Q1 		$19K Sell
651
-7,960
-92% -$213K ﹤0.01% 2137
2023
Q4 		$192K Sell
8,611
-4,898
-36% -$110K ﹤0.01% 1697
2023
Q3 		$334K Sell
13,509
-15,631
-54% -$413K ﹤0.01% 1616
2023
Q2 		$825K Buy
29,140
+2,038
+8% +$50.7K ﹤0.01% 1462
2023
Q1 		$623K Buy
27,102
+2,851
+12% +$75.7K ﹤0.01% 1543
2022
Q4 		$681K Buy
24,251
+165
+0.7% +$4.65K ﹤0.01% 1519
2022
Q3 		$681K Sell
24,086
-190
-0.8% -$5.1K ﹤0.01% 1521
2022
Q2 		$538K Sell
24,276
-7,792
-24% -$176K ﹤0.01% 1562
2022
Q1 		$933K Sell
32,068
-2,221
-6% -$67.9K ﹤0.01% 1916
2021
Q4 		$1.13M Buy
+34,289
New +$1.38M ﹤0.01% 1860

Other funds holding AGIO

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Allspring Global Investments's AGIO Position: Q4 2024 in Review

Allspring Global Investments sold out of Agios Pharmaceuticals (AGIO) in Q4 2024, closing a stake of 425 shares — an estimated $18.9K sold.

Allspring Global Investments first reported a position in AGIO in Q4 2021 and held it in 12 quarters. The position peaked at $1.13M in Q4 2021. 225 funds tracked by Wall St. Rank hold AGIO as of Q4 2024.

  • Allspring Global Investments reported no remaining Agios Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Allspring Global Investments sold 425 Agios Pharmaceuticals shares in Q4 2024, an estimated $18.9K.
  • Allspring Global Investments first reported a position in Agios Pharmaceuticals in Q4 2021 and held it in 12 quarters.
  • Allspring Global Investments's Agios Pharmaceuticals position peaked at $1.13M in Q4 2021.
  • 225 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2024.

Based on Allspring Global Investments's 13F filing for Q4 2024, filed 29 Jan 2025.